Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30379976 | 1.00 | DGAT1 (0.32) | DGAT1PTGER4NPC1 | |
| SCHEMBL24150835 | 0.86 | DGAT1 (0.33) | DGAT1PTGER4NPC1 | |
| SCHEMBL19960802 | 0.84 | PTGER4 (0.32) | PTGER4 | |
| SCHEMBL23783034 | 0.81 | NPC1 (0.31) | DGAT1PTGER4NPC1 | |
| SCHEMBL25168187 | 0.81 | DGAT1 (0.31) | DGAT1PTGER4 | |
| SCHEMBL19948808 | 0.81 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL25344551 | 0.80 | NPC1 (0.33) | DGAT1NPC1 | |
| SCHEMBL29907034 | 0.79 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL23211119 | 0.79 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL24150514 | 0.79 | DGAT1 (0.35) | DGAT1PTGER4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516059-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-20240383889-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-11-21 | — | — | US | disclosed |
| US-11891388-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20220227752-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2022-07-21 | — | — | US | disclosed |
| US-11242343-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-11242343-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| WO-2021262596-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20200283434-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-20200283434-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-20190315743-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-10-17 | — | — | US | disclosed |
| US-20190315743-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-10-17 | — | — | US | disclosed |
| WO-2018049214-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180072718-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20180072718-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20180072718-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383889-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | DGAT1 4418/4885PTGER4 2999/4885NPC1 754/4885 |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | DGAT1 2417/4885PTGER4 4554/4885NPC1 2575/4885 |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | DGAT1 2467/4885PTGER4 4741/4885NPC1 327/4885 |
| US-11242343-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | DGAT1 4418/4885PTGER4 2999/4885NPC1 754/4885 |
| US-20190315743-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | DGAT1 4418/4885PTGER4 2999/4885NPC1 754/4885 |
| US-20180072718-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | DGAT1 4418/4885PTGER4 2999/4885NPC1 754/4885 |
| US-20200283434-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | DGAT1 4418/4885PTGER4 2999/4885NPC1 754/4885 |
| US-20220227752-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | DGAT1 4418/4885PTGER4 2999/4885NPC1 754/4885 |
| US-11891388-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | DGAT1 4418/4885PTGER4 2999/4885NPC1 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.